Announcement • Jul 22
Mobia Medical, Inc. to Report Q2, 2026 Results on Aug 11, 2026 Mobia Medical, Inc. announced that they will report Q2, 2026 results on Aug 11, 2026 Announcement • Jul 16
Mobia Medical, Inc. Announces Appointment of Reza Zadno as Independent Director and Member of Compensation Committee, Effective July 14, 2026 Mobia Medical, Inc. announced the appointment of Reza Zadno, Ph.D., to the Board as an independent director, effective July 14, 2026. Dr. Zadno will also serve as a member of the Compensation Committee. Dr. Zadno brought more than 35 years of medical technology experience, with a track record of building and leading commercial-stage companies through IPO and beyond. He served as President and CEO, and as a director at PROCEPT BioRobotics, a surgical robotics company, from February 2020 to September 2025, leading the company through its 2021 IPO and a period of significant commercial expansion. From September 2016 to November 2020, he served as President and CEO, and as a member of the board of directors at Avedro, a public ophthalmology company prior to its acquisition by Glaukos. Between January 2013 and June 2017, Dr. Zadno served on the board of directors and audit committee of Invuity, Inc., a public medical device company, prior to its acquisition by Stryker. From June 2013 through November 2016, he served on the board of directors and audit committee of Carbylan Therapeutics, a public biopharmaceutical company, prior to its merger with KalVista Pharmaceuticals. Dr. Zadno currently serves as an Operating Partner at Jolt Capital, a private equity firm specializing in growth-stage technology investments, and as a Special Advisor to the American Academy of Ophthalmology. He received a Ph.D. and M.Sc. in Mechanical Properties of Materials (Metallurgy) from École Nationale Supérieure de Mines de Paris. Announcement • Jul 15
Mobia Medical Publishes Two-Year Data From VNS-REHAB Trial Demonstrating Durable Stroke Recovery With Vivistim Paired VNS Therapy Mobia Medical, Inc. announced the publication of two-year follow-up data from the VNS-REHAB study in Neurology, the official peer-reviewed journal of the American Academy of Neurology. The findings demonstrate that statistically significant and clinically meaningful improvements in upper-limb motor impairment and function, ability to perform activities of daily living, and quality of life were sustained for at least two years following completion of in-clinic Vivistim Paired VNS Therapy. The two-year follow-up data, published in Neurology, reports outcomes from 49 participants in the VNS-REHAB pivotal trial, demonstrating a high responder rate and substantial improvements in impairment and function including: Clinically meaningful response on the Fugl-Meyer Assessment of Upper Extremity impairment (FMA-UE) and/or the Wolf Motor Function Test (WMFT) in 76% of participants; Average improvement of +7.5 points from baseline on the FMA-UE, exceeding the minimum clinically important difference (MCID) of =6 points; Average improvement of +0.63 from baseline on the WMFT, exceeding the MCID of =0.4 points. These upper-limb motor improvements also translated into impactful real-world changes in the daily lives of stroke survivors. Participants demonstrated statistically significant and clinically meaningful improvements across multiple patient-reported measures of activity, participation, and quality of life, including: Ability to perform activities of daily living, such as bathing and dressing (Activities of Daily Living subscale of the Stroke Impact Scale; SIS-ADL); Perceived ease of performing daily activities with the affected hand and arm, such as carrying heavy objects or tying shoelaces (Hand subscale of the Stroke Impact Scale; SIS-Hand); Amount of use and quality of movement of the affected hand and arm when performing activities of daily living, such as brushing teeth or typing (Motor Activity Log; MAL); Overall stroke-specific quality of life, such as mood, self-care, social participation and family roles (Stroke-Specific Quality of Life Scale; SS-QOL). The study also captures positive three-year outcomes from 16 participants, providing further supporting evidence that the benefits are durable and maintained long-term. Additionally, a subset of the 49 total participants experienced further improvement in scores between years one and two, suggesting that recovery may continue over time with ongoing self-directed Vivistim Therapy. In addition to data from patients enrolled in the VNS-REHAB trial, clinicians have observed similar long-term results in some of their earliest commercially treated patients. The formal publication of these findings further validates the durability of observed in-clinic results. The VNS-REHAB trial was a multicenter, triple-blinded, sham-controlled randomized controlled trial (n=108 participants) evaluating the safety and efficacy of Vivistim Paired VNS Therapy in chronic ischemic stroke survivors with moderate to severe upper extremity impairment. The pivotal results were published in The Lancet and supported FDA Premarket Approval of the Vivistim System in 2021. One-year follow-up data, published in Stroke in 2025, confirmed improvements were maintained at 12 months and the two-year data, now published in Neurology, further extend these findings. No long-term serious adverse events related to the therapy or stimulation were reported through two years of follow-up. 
